February 20, 2017 6:42am NASDAQ:IBB
The biotech sector has gotten a lot of attention lately both in the financial markets and in Washington. The sector, which was one of the worst performing areas of the market in 2016 posting a loss of more than 20%, has started posting gains again and is looking like the rally may be poised to continue.
The biggest play in the sector, the iShares Nasdaq Biotechnology ETF (IBB), is up more than 10% on the year (its smaller equal weight counterpart, the SPDR S&P Biotech ETF (XBI), is up over 17%).
The sector has alternatively gotten good and bad news from the White House. For many months, there has been talk of lowering drug prices through open competition or price caps putting pressure on the big drug manufacturers. On the other hand, President Trump spoke recently of his desire to reform the entire drug approval process in order to speed the approval of life-saving medications and cutting the red tape at the FDA. That notion was welcomed by the equity markets even though it received a tepid response from big pharma companies.
One thing working in favor of biotech right now is M&A and the big prize could be Bristol-Myers Squibb (BMY). A StreetInsider article from this week called the company in play and listed Roche (RHHBY), Novartis (NVS), Gilead (GILD) and Pfizer (PFE) all as potential buyers. Acadia Pharmaceuticals (ACAD) could also be up for grabs with Biogen (BIBB) rumored to be a possible bidder. In its quarterly analyst meeting, Amgens (AMGN) CEO Bob Bradway discussed how his company was going to be on the lookout for acquisitions both big and small.
Even Gilead, the big biotech that just caught Wall Street off guard when it significantly lowered 2017 revenue guidance due to weak sales in its hepatitis C drugs, even provided some reason for optimism. The stock dropped roughly 10% on its weak forecast, from a pre-earnings level of around $73 down to a post-announcement low in the $65 area. Since then, however, it has, somewhat surprisingly, begun rallying anew. The stock closed Friday at $70, gaining back nearly of what was lost. Does this signal something of a capitulation point and indicate that buyers are ready to return?
From a technical standpoint, the fund just broke out to the upside from a wedge pattern that has been forming over the past several months.
I wrote earlier this month that I felt the Biotech ETF could close out February above $300 if it could break through the resistance level around $285. It has and now it feels like that $300 level is well within reach.
Despite its rally so far this year, the fund is still about 13% off of its 2016 highs and 26% off of its all-time highs. Valuations in the sector look very reasonable right now as well. Thomson Reuters estimates put the forward P/E of the sector at less than 13, a level it hasnt seen in several years.
Gileads results notwithstanding, the Q4 earnings season has been pretty good for biotech. Big players such as Amgen, Celgene (CELG), Illumina (ILMN) and Vertex Pharmaceuticals (VRTX) all top 10 holdings in the fund popped strongly after announcing earnings. If the sector can continue posting generally good revenue and earnings results and get a little help from the White House along the way, this could be a nice spot to add a few shares.
The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) closed at $294.35 on Friday, up $1.37 (+0.47%). Year-to-date, IBB has gained 10.92%, versus a 5.17% rise in the benchmark S&P 500 index during the same period.
IBB currently has an ETF Daily News SMART Grade of A (Strong Buy), and is ranked #2 of 36 ETFs in the Health & Biotech ETFs category.
About the Author: David Dierking
David Dierking is a freelance writer focusing primarily on ETFs, mutual funds, dividend income strategies and retirement planning. He has spent more than 20 years in the financial services industry and his background includes experience in investment management, portfolio analytics and asset/liability management at both BMO Financial Group and Strong Capital Management.
He has written for Seeking Alpha, Motley Fool, ETF Trends and Investopedia and was also included in the panel for ETFReference.coms 101 ETF Investing Tips from the Experts. He has a B.A. in Finance from Michigan State University and lives in Wisconsin with his wife and two daughters.
You can connect with David on Twitter and LinkedIn. Also be sure to visit his new website, ETFFocus.com.
Tags: biotech david dierking NASDAQ:IBB
Categories: NASDAQ:IBB
See more here:
This Biotech ETF Looks Primed To Rally Again - ETF Daily News (blog)
- Is Weakness In Bloomage BioTechnology Corporation Limited (SHSE:688363) Stock A Sign That The Market Could be ... - Simply Wall St - March 28th, 2024
- Insiders were the biggest winners as Beijing Bohui Innovation Biotechnology Group Co., Ltd.'s (SZSE:300318) market ... - Simply Wall St - March 28th, 2024
- Biotechnology CEO and inventor of SiriusXM Satellite Radio Martine Rothblatt to deliver graduation address to the ... - EurekAlert - March 28th, 2024
- 6 biotechnology universities in the UK leading the way for future talent - Labiotech.eu - March 28th, 2024
- Is Vera Therapeutics Inc (VERA) a Bad Choice in Biotechnology Wednesday? - InvestorsObserver - March 28th, 2024
- Is G1 Therapeutics Inc (GTHX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - March 28th, 2024
- The three-year underlying earnings growth at Anhui Anke Biotechnology (Group) (SZSE:300009) is promising, but the ... - Simply Wall St - March 28th, 2024
- Is Lyra Therapeutics Inc (LYRA) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - March 28th, 2024
- Should You Sell 4D Molecular Therapeutics Inc (FDMT) in Biotechnology Industry? - InvestorsObserver - March 28th, 2024
- SPMVV receives 47.9 lakh grant from the governments Department of Biotechnology - The Hindu - March 28th, 2024
- Where Does IGC Pharma Inc (IGC) Stock Fall in the Biotechnology Field After It Is Up 14.71% This Week? - InvestorsObserver - March 28th, 2024
- Report Lays Out Road Map to Transform Understanding of RNA and Invest in RNA Science and Biotechnology - National Academies of Sciences, Engineering,... - March 28th, 2024
- Is Akebia Therapeutics Inc (AKBA) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - March 28th, 2024
- Singapore and Indonesia to foster bilateralism in healthcare, digital health, and biotechnology - BSA bureau - March 28th, 2024
- Where Does Gossamer Bio Inc (GOSS) Stock Fall in the Biotechnology Field After It Is Lower By -14.07% This Week? - InvestorsObserver - March 28th, 2024
- Where Does Equillium Inc (EQ) Stock Fall in the Biotechnology Field After It Is Down -31.25% This Week? - InvestorsObserver - March 28th, 2024
- Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin - FDA.gov - January 14th, 2024
- An Introduction to Biotechnology - PMC - National Center for ... - January 14th, 2024
- Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? - Yahoo Finance - January 14th, 2024
- Digital Life Norway (DLN) Initiative to foster and boost transdisciplinary biotechnology research and innovation - Open Access Government - January 14th, 2024
- Is Elevation Oncology Inc (ELEV) a Bad Choice in Biotechnology Thursday? - InvestorsObserver - January 14th, 2024
- Is Cytokinetics, Inc. (CYTK) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 14th, 2024
- Is Regeneron Pharmaceuticals Inc (REGN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 14th, 2024
- Is Axsome Therapeutics Inc (AXSM) a Good Buy in the Biotechnology Industry? - InvestorsObserver - January 14th, 2024
- Where Does Immunovant Inc (IMVT) Stock Fall in the Biotechnology Field After It Is Higher By 11.63% This Week? - InvestorsObserver - January 14th, 2024
- Should Biotechnology Stock Harpoon Therapeutics Inc (HARP) Be in Your Portfolio Wednesday? - InvestorsObserver - November 24th, 2023
- Should Biotechnology Stock SpringWorks Therapeutics Inc (SWTX) Be in Your Portfolio Wednesday? - InvestorsObserver - November 24th, 2023
- Where Does Cassava Sciences Inc (SAVA) Stock Fall in the Biotechnology Field After It Has Fallen -1.24% This Week? - InvestorsObserver - November 24th, 2023
- Where Does Kalvista Pharmaceuticals Inc (KALV) Stock Fall in the Biotechnology Field After It Is Lower By -1.04% This Week? - InvestorsObserver - November 24th, 2023
- Should Biotechnology Stock Theravance Biopharma Inc (TBPH) Be in Your Portfolio Thursday? - InvestorsObserver - April 23rd, 2023
- Where Will Sana Biotechnology Inc (SANA) Stock Go Next After It Is Down 1.35% in a Week? - InvestorsObserver - April 23rd, 2023
- Where Does Novo Nordisk A/S (NVO) Stock Fall in the Biotechnology Field After It Has Fallen -1.71% This Week? - InvestorsObserver - April 23rd, 2023
- Where Does Seagen Inc (SGEN) Stock Fall in the Biotechnology Field After It Is Lower By -0.81% This Week? - InvestorsObserver - April 23rd, 2023
- MSc Admissions at Institute of Bioinformatics and Applied Biotechnology, Bengaluru - Mathrubhumi English - April 23rd, 2023
- What is Biotechnology? Definition, Types and Applications | TechTarget - March 28th, 2023
- Biotechnology - Applications of biotechnology | Britannica - March 28th, 2023
- Biotechnology | FAO | Food and Agriculture Organization of the United ... - March 28th, 2023
- What is Biotechnology? Types and Applications - Iberdrola - March 28th, 2023
- Should Biotechnology Stock Checkpoint Therapeutics Inc (CKPT) Be in Your Portfolio Monday? - InvestorsObserver - March 28th, 2023
- Where Does IGM Biosciences Inc (IGMS) Stock Fall in the Biotechnology Field After It Has Fallen -1.80% This Week? - InvestorsObserver - March 28th, 2023
- Is Day One Biopharmaceuticals Inc (DAWN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - March 28th, 2023
- Where Does Jasper Therapeutics Inc (JSPR) Stock Fall in the Biotechnology Field After It Has Risen 3.16% This Week? - InvestorsObserver - March 28th, 2023
- Is Evaxion Biotech A/S - ADR (EVAX) a Leader in the Biotechnology Industry? - InvestorsObserver - February 14th, 2023
- Where Does Oncolytics Biotech Inc (ONCY) Stock Fall in the Biotechnology Field After It Has Risen 1.72% This Week? - InvestorsObserver - February 14th, 2023
- Where Does Surrozen Inc (SRZN) Stock Fall in the Biotechnology Field After It Is Up 59.74% This Week? - InvestorsObserver - February 14th, 2023
- International Biotechnology Trust's Investment Manager to Focus on Core Healthcare Business - Marketscreener.com - February 14th, 2023
- Where Does Ocugen Inc (OCGN) Stock Fall in the Biotechnology Field After It Is Lower By -14.73% This Week? - InvestorsObserver - February 14th, 2023
- Is Protagonist Therapeutics Inc (PTGX) a Smart Choice in Biotechnology Friday? - InvestorsObserver - February 14th, 2023
- Where Does Kiora Pharmaceuticals Inc (KPRX) Stock Fall in the Biotechnology Field After It Has Risen 33.24% This Week? - InvestorsObserver - February 14th, 2023
- Where Does Novavax Inc (NVAX) Stock Fall in the Biotechnology Field After It Is Up 0.46% This Week? - InvestorsObserver - February 14th, 2023
- City of Vacaville Introduces Next Generation to Biotechnology and Advanced Manufacturing - Financial Post - February 6th, 2023
- Is Incyte Corporation (INCY) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - February 6th, 2023
- Where Does Catalyst Pharmaceuticals Inc (CPRX) Stock Fall in the Biotechnology Field After It Is Down -3.88% This Week? - InvestorsObserver - February 6th, 2023
- Where Does Summit Therapeutics Inc (SMMT) Stock Fall in the Biotechnology Field After It Is Up 8.63% This Week? - InvestorsObserver - February 6th, 2023
- Where Does Compass Therapeutics Inc. (CMPX) Stock Fall in the Biotechnology Field After It Is Down -2.89% This Week? - InvestorsObserver - February 6th, 2023
- Should You Be Impressed By Puma Biotechnology, Inc.'s (NASDAQ:PBYI) ROE? - Simply Wall St - January 21st, 2023
- Where Does Palisade Bio Inc (PALI) Stock Fall in the Biotechnology Field After It Is Lower By -11.27% This Week? - InvestorsObserver - January 21st, 2023
- Is Autolus Therapeutics PLC (AUTL) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 21st, 2023
- Where Does Edesa Biotech Inc (EDSA) Stock Fall in the Biotechnology Field After It Has Fallen -39.16% This Week? - InvestorsObserver - January 21st, 2023
- Where Does Vaxcyte Inc (PCVX) Stock Fall in the Biotechnology Field After It Has Fallen -7.21% This Week? - InvestorsObserver - January 12th, 2023
- Where Does CytomX Therapeutics Inc (CTMX) Stock Fall in the Biotechnology Field After It Is Up 61.68% This Week? - InvestorsObserver - January 12th, 2023
- Where Does Vyant Bio Inc (VYNT) Stock Fall in the Biotechnology Field After It Is Up 36.36% This Week? - InvestorsObserver - January 12th, 2023
- Is CTI BioPharma Corp (CTIC) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 12th, 2023
- Where Does Jaguar Health Inc (JAGX) Stock Fall in the Biotechnology Field After It Has Gained 22.22% This Week? - InvestorsObserver - January 12th, 2023
- Where Does Geron Corporation (GERN) Stock Fall in the Biotechnology Field After It Has Gained 9.09% This Week? - InvestorsObserver - January 12th, 2023
- Is OncoSec Medical Inc (ONCS) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 12th, 2023
- What is Biotechnology? Master of Biotechnology - January 4th, 2023
- Where Does Chemomab Therapeutics Ltd - ADR (CMMB) Stock Fall in the Biotechnology Field After It Has Gained 52.97% This Week? - InvestorsObserver - January 4th, 2023
- Should Biotechnology Stock Galera Therapeutics Inc (GRTX) Be in Your Portfolio Wednesday? - InvestorsObserver - January 4th, 2023
- Where Does 180 Life Sciences Corp (ATNF) Stock Fall in the Biotechnology Field After It Is Lower By -26.07% This Week? - InvestorsObserver - January 4th, 2023
- Is Adaptive Biotechnologies Corp (ADPT) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 4th, 2023
- Is ImmunoGen, Inc. (IMGN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 4th, 2023
- Is DBV Technologies SA - ADR (DBVT) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 4th, 2023
- Does PDS Biotechnology Corp (PDSB) Have What it Takes to be in Your Portfolio Wednesday? - InvestorsObserver - December 27th, 2022
- Where Does Intercept Pharmaceuticals Inc (ICPT) Stock Fall in the Biotechnology Field After It Is Lower By -10.50% This Week? - InvestorsObserver - December 27th, 2022
- Where Does Merrimack Pharmaceuticals Inc (MACK) Stock Fall in the Biotechnology Field After It Has Fallen -10.39% This Week? - InvestorsObserver - December 27th, 2022
- Where Does Compass Therapeutics Inc. (CMPX) Stock Fall in the Biotechnology Field After It Is Higher By 2.68% This Week? - InvestorsObserver - December 27th, 2022
- Where Does Allogene Therapeutics Inc (ALLO) Stock Fall in the Biotechnology Field After It Is Lower By -19.38% This Week? - InvestorsObserver - December 27th, 2022
- Where Does Oramed Pharmaceuticals, Inc. (ORMP) Stock Fall in the Biotechnology Field After It Is Higher By 11.42% This Week? - InvestorsObserver - December 27th, 2022
- Is Calithera Biosciences Inc (CALA) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - December 27th, 2022